Aspiriant LLC lifted its holdings in shares of Pfizer, Inc. (NYSE:PFE) by 2.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 38,427 shares of the biopharmaceutical company’s stock after purchasing an additional 776 shares during the quarter. Aspiriant LLC’s holdings in Pfizer were worth $1,291,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PFE. Shine Investment Advisory Services Inc. acquired a new position in Pfizer during the 2nd quarter worth about $102,000. D. Scott Neal Inc. lifted its stake in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 504 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC acquired a new position in Pfizer during the 1st quarter worth about $121,000. Cascade Investment Advisors Inc. lifted its stake in Pfizer by 89.1% during the 2nd quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 2,200 shares in the last quarter. Finally, Perennial Advisors LLC lifted its stake in Pfizer by 7.9% during the 2nd quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 376 shares in the last quarter. Institutional investors and hedge funds own 69.34% of the company’s stock.

Shares of Pfizer, Inc. (NYSE PFE) opened at $35.54 on Wednesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer, Inc. has a 12-month low of $30.51 and a 12-month high of $36.78. The firm has a market capitalization of $211,840.00, a PE ratio of 14.15, a PEG ratio of 2.50 and a beta of 1.01.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter last year, the business posted $0.61 EPS. research analysts forecast that Pfizer, Inc. will post 2.6 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.60%. Pfizer’s dividend payout ratio is presently 78.53%.

Several equities analysts recently issued reports on PFE shares. UBS AG reissued a “buy” rating and set a $38.00 target price on shares of Pfizer in a research note on Monday, July 31st. Berenberg Bank set a $39.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, August 1st. BMO Capital Markets raised Pfizer from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $33.00 to $37.00 in a research note on Wednesday, August 2nd. Jefferies Group LLC set a $35.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Finally, BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $38.48.

TRADEMARK VIOLATION NOTICE: “Pfizer, Inc. (PFE) Shares Bought by Aspiriant LLC” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/11/22/pfizer-inc-pfe-shares-bought-by-aspiriant-llc.html.

In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the transaction, the executive vice president now owns 117,432 shares in the company, valued at approximately $4,186,450.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the transaction, the insider now owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Insiders have sold a total of 366,557 shares of company stock worth $12,532,406 in the last 90 days. 0.06% of the stock is currently owned by company insiders.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.